Business
Willow Biosciences Announces Expansion of its Commercial Operations Team and Development Portfolio, an Update on its Intellectual Property Position, and Formation of ESG Committee
Willow Biosciences Announces Expansion of its Commercial Operations Team and Development ...
About this update from Atlas Energy Corp.
[{"type":"text","content":"\n \n \n \n Willow Biosciences Announces Expansion of its Commercial Operations Team and Development Portfolio, an Update on its Intellectual Property Position, and Formation of ESG Committee\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n VANCOUVER, BC\n \n ,\n \n July 20, 2021\n \n /CNW/ - Willow Biosciences Inc. (\"\n \n Willow\n \n \" or the \"\n \n Company\n \n \") (TSX: WLLW) (OTCQX: CANSF), a leading biotechnology company that manufactures ultra-pure, sustainably produced cannabinoids via yeast-based biosynthesis, is pleased to provide an update on its operations as it transitions to a production company and expands its R&D capabilities to accommodate additional development programs, including cannabinol (\"\n \n CBN\n \n \").\n \n \n \n \n \n \n \n \n \n \n Expansion of Commercial Operations and R&D Teams\n \n \n \n With its lead program, cannabigerol (\"\n \n CBG\n \n \"), now successfully at manufacturing scale, Willow has added resources and expertise to manage commercial production and further expand its R&D capabilities to grow its product portfolio. Willow has expanded its\n \n Vancouver, British Columbia\n \n and\n \n Mountain View, California\n \n teams to include manufacturing, quality and regulatory groups, along with additional R&D scientists focusing on strain optimization and process development. Willow's total headcount is now 55 employees, 42 of which are in technical roles.\n \n \n \n Expansion of Development Portfolio\n \n \n \n With Willow's lead proprietary yeast strain now producing biosynthetic CBG at commercial scale, and agreements in place to generate product revenue, Willow's R&D teams are now focused on development of cannabidiol (\"\n \n CBD\n \n \") and tetrahydrocannabinol (\"\n \n THC\n \n \") programs for commercial manufacture. In addition to Willow's commercial development programs for CBG, CBD and THC, Willow's R&D team continues to develop biosynthetic processes for cannabidivarin (\"\n \n CBDV\n \n \"), cannabigerovarin (\"\n \n CBGV\n \n \"), and te...